Prilenia

Prilenia is a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders.

Prilenia is developing treatments for neurodegenerative & neurodevelopmental disorders Improving lives of patients & their families.

Prilenia was founded in 2018 by Michael R. Hayden. The company is headquartered in Herzliya, Naarden, Israel, with an office in Netherlands.

 

Prilenia's lead asset is Pridopidine, a first-in-class drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.

 

Pridopidine is orally administered with therapeutic potential in HD, ALS and other neurodegenerative diseases and neurodevelopmental disorders such as Rett and Fragile-X syndromes.

 

Prilenia is backed Sands Capital, Talisman Capital Partners, Morningside Venture Investments, Forbion, Amplitude Ventures, Genworks 2, Sectoral Asset Management, and others. The company raised $43M in Series B round on Nov 03, 2021. This brings Prilenia's total funding to $127.5M to date.

 

 

 

  • Year founded: 2018
  • Funding Info: $127.5M over 3 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Herzliya
  • State: Herzliya
  • Country: Israel
Related businesses